Evaluation of Microflow Digital Imaging Particle Analysis for Sub-Visible Particles Formulated with an Opaque Vaccine Adjuvant
Open Access
- 29 February 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (2) , e0150229
Abstract
Microflow digital imaging (MDI) has become a widely accepted method for assessing sub-visible particles in pharmaceutical formulations however, to date; no data have been presented on the utility of this methodology when formulations include opaque vaccine adjuvants. This study evaluates the ability of MDI to assess sub-visible particles under these conditions. A Fluid Imaging Technologies Inc. FlowCAM® instrument was used to assess a number of sub-visible particle types in solution with increasing concentrations of AddaVax™, a nanoscale squalene-based adjuvant. With the objective (10X) used and the limitations of the sensor resolution, the instrument was incapable of distinguishing between sub-visible particles and AddaVax™ droplets at particle sizes less than 5 μm. The instrument was capable of imaging all particle types assessed (polystyrene beads, borosilicate glass, cellulose, polyethylene protein aggregate mimics, and lysozyme protein aggregates) at sizes greater than 5 μm in concentrations of AddaVax™ up to 50% (vol:vol). Reduced edge gradients and a decrease in measured particle sizes were noted as adjuvant concentrations increased. No significant changes in particle counts were observed for polystyrene particle standards and lysozyme protein aggregates, however significant reductions in particle counts were observed for borosilicate (80% of original) and cellulose (92% of original) particles. This reduction in particle counts may be due to the opaque adjuvant masking translucent particles present in borosilicate and cellulose samples. Although the results suggest that the utility of MDI for assessing sub-visible particles in high concentrations of adjuvant may be highly dependent on particle morphology, we believe that further investigation of this methodology to assess sub-visible particles in challenging formulations is warranted.Keywords
This publication has 30 references indexed in Scilit:
- Subvisible (2-100 μm) Particle Analysis During Biotherapeutic Drug Product Development: Part 1, Considerations and StrategyJournal of Pharmaceutical Sciences, 2015
- Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methodsEuropean Journal of Pharmaceutical Sciences, 2014
- Development of a Stable Virus-Like Particle Vaccine Formulation against Chikungunya Virus and Investigation of the Effects of PolyanionsJournal of Pharmaceutical Sciences, 2013
- Adjuvants and Immunization Strategies to Induce Influenza Virus Hemagglutinin Stalk AntibodiesPLOS ONE, 2013
- The Physical Stability of the Recombinant Tuberculosis Fusion Antigens H1 and H56Journal of Pharmaceutical Sciences, 2013
- Immunogenicity of therapeutic proteins: Influence of aggregationJournal of Immunotoxicology, 2013
- Micro–Flow Imaging and Resonant Mass Measurement (Archimedes) – Complementary Methods to Quantitatively Differentiate Protein Particles and Silicone Oil DropletsJournal of Pharmaceutical Sciences, 2013
- Quantification and Characterization of Subvisible Proteinaceous Particles in Opalescent mAb Formulations Using Micro-Flow ImagingJournal of Pharmaceutical Sciences, 2010
- Critical Evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the Measurement of Nanoparticles and Protein AggregatesPharmaceutical Research, 2010
- Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product QualityJournal of Pharmaceutical Sciences, 2009